Why is Ino stock going up?
Also recently, INO stock jumped after the company dosed the first participant in a study to vaccinate against Middle East Respiratory Syndrome, or MERS. The illness is caused by a coronavirus. It's more fatal than Covid, though far less common.
Where can I buy Ino shares?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Should you hold Inovio Pharmaceuticals (Ino) stock?
The consensus among Wall Street analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
When is the Ino earnings call?
INO earnings call for the period ending December 31, 2019. INO earnings call for the period ending September 30, 2019. INO earnings call for the period ending June 30, 2019. Primary metrics and data points about Inovio Pharmaceuticals. Learn more about CAPS!
Is INO stock a good buy?
INO stock isn't a buy in December 2021. Shares aren't forming a specific chart pattern and, based on technical analysis, aren't showing the marks of winning stocks — strong growth in sales and earnings. Investors are encouraged to buy a stock when it tops a buy point and is less than 5% extended from that entry.
What is the future of INO stock?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 2.50, with a high estimate of 8.00 and a low estimate of 1.00. The median estimate represents a +39.66% increase from the last price of 1.79.
Will INO stock go back up?
Based on our forecasts, a long-term increase is expected, the "INO" stock price prognosis for 2027-06-11 is 3.660 USD. With a 5-year investment, the revenue is expected to be around +153.29%. Your current $100 investment may be up to $253.29 in 2027.
What is going on with Inovio?
Inovio Pharmaceuticals Inc will discontinue a late-stage study of its COVID-19 vaccine, the company said on Tuesday, and appointed its operating chief as the new chief executive, sending the company's shares down nearly 20% after the bell.
What is Nio price target?
The 30 analysts offering 12-month price forecasts for NIO Inc have a median target of 30.25, with a high estimate of 82.37 and a low estimate of 21.94.
Is Novavax publicly traded?
Common Stock (NVAX)
Why is Ino tanking?
[Updated: Dec 17, 2021] INO Stock Decline This can be attributed to the spread of the new Covid-19 variant - Omicron. Inovio is developing INO-4800 - its Covid-19 vaccine candidate, which is now in late stage clinical trials and it is still several months before it can hit the market, subject to regulatory approval.
How does inovio Covid vaccine work?
INO-4800 is administered intradermally with a proprietary device, CELLECTRA 3PSP, designed by INOVIO to deliver optimized DNA into cells in the hope that these cells will be translated into proteins that generate a robust targeted T cell and antibody response to SARS-CoV-2.
Who founded Inovio Pharmaceuticals?
J. Joseph KimAlso in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Inovio was co-founded by President, CEO, and Director, J. Joseph Kim, Ph. D, and David B.
Where is Inovio Pharmaceuticals located?
Plymouth Meeting, PennsylvaniaInovio PharmaceuticalsTypePublicHeadquartersPlymouth Meeting, PennsylvaniaKey peopleJ. Joseph Kim (President and CEO)ProductsDNA based medicines and VaccinesRevenue$7 Million(2020)6 more rows
Should I buy or sell Inovio Pharmaceuticals stock right now?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 5 ho...
What is Inovio Pharmaceuticals' stock price forecast for 2022?
5 Wall Street research analysts have issued 12-month price objectives for Inovio Pharmaceuticals' shares. Their forecasts range from $3.00 to $35.0...
How has Inovio Pharmaceuticals' stock price performed in 2022?
Inovio Pharmaceuticals' stock was trading at $4.99 on January 1st, 2022. Since then, INO shares have decreased by 69.7% and is now trading at $1.51...
Are investors shorting Inovio Pharmaceuticals?
Inovio Pharmaceuticals saw a drop in short interest in the month of May. As of May 31st, there was short interest totaling 34,410,000 shares, a dro...
When is Inovio Pharmaceuticals' next earnings date?
Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for...
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) posted its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) earning...
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals shares reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of s...
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the following people: Dr. J. Joseph Kim Ph.D. , CEO, Pres & Director (Age 53, Pay $1.31M) Mr. P...
What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?
12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com . J. Joseph Kim has an approval rating of 82% among Inovio Pharm...
About Inovio Pharmaceuticals
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B.
Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates
6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Inovio Pharmaceuticals stock.
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nasdaq Global Select
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Environmental, Social, and Governance Rating
A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.
Business Summary
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Signals & Forecast
A biomedical company which deals in developing human applications of electroporation, which uses brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceuticals.
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Is Inovio Pharmaceuticals stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Insiders are neutral selling more shares than they are buying in Inovio Pharmaceuticals
Inovio Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Inovio Pharmaceuticals
In the last 100 trades there were 1.12 million shares bought and 1.25 million shares sold. The last trade was done 37 days ago by Benito Simon X who sold 2 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Golden Star Signal
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
A Look At INO Stock Fundamentals
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Inovio Stock Background
First, it's important to note Inovio isn't profitable and expects continued losses in the foreseeable future. In the third quarter, Inovio reported a 29-cent loss per share and $292,000 in revenue. Losses were narrower than expected, but sales missed forecasts.
Gates Foundation, CEPI Award Inovio Grants
Inovio was founded in 1983 under another name, Genetronics. At the time, it focused on a technological platform called electroporation. Electroporation is using controlled electrical pulses to create openings in cells. In theory, that should make them more permeable to drugs and other agents.
Technical Analysis Of INO Stock
After merging with VGX, Inovio began focusing on DNA vaccines and electroporation delivery. Electroporation uses a medical device to deliver a low electric shock at the injection site. This is meant to coax the drug into cells.
INO Stock: Coronavirus Vaccine News
Inovio stock hit a high mark of 33.79 in June 2020 after the biotech company received a $71 million contract from the U.S. Department of Defense to scale up manufacturing for its coronavirus vaccine. But in April, shares plummeted after the department withdrew funding for Phase 3 testing.
Is Inovio Stock A Buy In December 2021?
The Department of Defense's decision to pull funding for final-phase testing wasn't based on Inovio or its Covid vaccine, the company said. Analysts say it's possible Inovio could still launch its vaccine and device internationally.
